Literature DB >> 21502448

Processing sentinel nodes in breast cancer: when and how many?

Samer Schuman1, Gail Walker, Eli Avisar.   

Abstract

OBJECTIVES: To analyze a series of sentinel nodes (SNs) from patients with node-positive breast cancer to determine their diagnostic value, to delineate a working algorithm, and to assess the clinical value of our common practice
DESIGN: A prospectively collected database.
SETTING: Tertiary referral center. PATIENTS: One hundred five patients with node-positive breast cancer who underwent SN biopsy. MAIN OUTCOME MEASURES: The diagnostic value of SNs by analyzing the sensitivity of processing the hottest, 2 hottest, hot and blue, or hot, blue, and suspicious SNs.
RESULTS: Three hundred fifty-three axillary SNs were recorded in the database. An analysis of the 282 radioactive axillary nodes for which the 10-second count was recorded reveals that the most radioactive node was positive in 73 of 94 analyzable patients (77.7%). Consideration of the 2 most intense axillary nodes was sufficient to diagnose nodal disease in an additional 12 patients, representing a significant increase in sensitivity to 90.4% (P < .001). Examination of all other radioactive nodes did not diagnose any additional cases. On the basis of all 105 patients, consideration of nonradioactive blue axillary nodes did not add significant diagnostic value relative to testing only radioactive nodes: sensitivity of 86.7% vs 88.6% (P = .50), whereas consideration of all hot, blue, and suspicious nodes improved sensitivity to 96.2% (P = .002).
CONCLUSIONS: Processing of the 2 hottest nodes, along with suspicious but nonhot and nonblue nodes, is sufficient for initial axillary staging. Additional radioactive SNs should be processed only in the presence of nodal disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21502448     DOI: 10.1001/archsurg.2011.29

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

1.  The Role of Blue Dye in Sentinel Node Detection for Breast Cancer: A Retrospective Study of 203 Patients.

Authors:  Jean-Remi Garbay; Dounia Skalli-Chrisostome; Nicolas Leymarie; Benjamin Sarfati; Francoise Rimareix; Chafika Mazouni
Journal:  Breast Care (Basel)       Date:  2016-04-26       Impact factor: 2.860

2.  Showcase of Intraoperative 3D Imaging of the Sentinel Lymph Node in a Breast Cancer Patient using the New Freehand SPECT Technology.

Authors:  Andreas Schnelzer; Alexandra Ehlerding; Christina Blümel; Asli Okur; Klemens Scheidhauer; Stefan Paepke; Marion Kiechle
Journal:  Breast Care (Basel)       Date:  2012-12       Impact factor: 2.860

3.  Value of Quantitative SPECT/CT Lymphoscintigraphy in Improving Sentinel Lymph Node Biopsy in Breast Cancer.

Authors:  Ting Luan; Yongqing Li; Qingwei Wu; Yan Wang; Zongwei Huo; Xiaohui Wang; Ligang Xing; Xiaorong Sun
Journal:  Breast J       Date:  2022-03-28       Impact factor: 2.269

4.  The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer.

Authors:  Francesco Giammarile; Naomi Alazraki; John N Aarsvold; Riccardo A Audisio; Edwin Glass; Sandra F Grant; Jolanta Kunikowska; Marjut Leidenius; Valeria M Moncayo; Roger F Uren; Wim J G Oyen; Renato A Valdés Olmos; Sergi Vidal Sicart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-02       Impact factor: 9.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.